August 2008: TauRx Closes US$35M Finance Round.
TauRx secured funds from new and existing investors to support the continued expansion and development of its pipeline of compounds for the diagnosis and treatment of Alzheimer’s disease and related disorders.
July 2008: Consultation with European EMEA.
TauRx met with representatives of the EMEA under the Scientific Advice Procedure to clarify clinical strategy, regulatory dossier and statistical design requirements for the further clinical evaluation of rember® in Alzheimer’s disease.
July 2008: TauRx Presents rember® Phase 2 AD Trial Results at ICAD.
The Company presented the results of its phase 2 rember® trial in 321 patients with mild or moderate Alzheimer’s disease at the International Conference for Alzheimer’s disease. rember® showed evidence of reducing the rate of progression of Alzheimer’s disease by 80%, compared to placebo, in this large, multinational trial.